Genmab 将来の成長

Future 基準チェック /46

Genmab利益と収益がそれぞれ年間8.8%と10.3%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に32.3% 7.5%なると予測されています。

主要情報

8.8%

収益成長率

7.48%

EPS成長率

Biotechs 収益成長	21.6%
収益成長率	10.3%
将来の株主資本利益率	32.30%
アナリストカバレッジ	Good
最終更新日	07 Jan 2026

今後の成長に関する最新情報

Genmab A/S Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 11

Genmab A/S Just Beat EPS By 44%: Here's What Analysts Think Will Happen Next

Feb 17

Recent updates

Here's Why We Think Genmab (CPH:GMAB) Might Deserve Your Attention Today

Sep 24

Investors Aren't Entirely Convinced By Genmab A/S' (CPH:GMAB) Earnings

Jul 31

Genmab A/S Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 11

It's Unlikely That The CEO Of Genmab A/S (CPH:GMAB) Will See A Huge Pay Rise This Year

Mar 06

Genmab A/S Just Beat EPS By 44%: Here's What Analysts Think Will Happen Next

Feb 17

Decisive Advances And DuoBody Innovation Propel Future Growth In Biotech Frontiers

Nov 11 Genmab's focus on late-stage therapies, particularly EPKINLY, is expected to boost future revenue and growth due to best-in-class technology and market approvals.

業績と収益の成長予測

CPSE:GMAB - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2028	5,818	1,981	2,820	2,413	7
12/31/2027	4,988	1,432	1,766	1,227	13
12/31/2026	4,287	1,010	1,397	920	14
12/31/2025	3,710	1,170	961	917	16
9/30/2025	3,846	1,583	1,294	1,369	N/A
6/30/2025	3,647	1,371	1,055	1,134	N/A
3/31/2025	3,231	1,140	1,124	1,194	N/A
12/31/2024	2,990	1,090	1,037	1,079	N/A
9/30/2024	2,964	702	980	1,005	N/A
6/30/2024	2,743	798	939	971	N/A
3/31/2024	2,576	791	775	818	N/A
12/31/2023	2,440	645	1,037	1,093	N/A
9/30/2023	2,389	590	806	866	N/A
6/30/2023	2,378	680	826	885	N/A
3/31/2023	2,216	757	902	955	N/A
12/31/2022	2,088	785	518	563	N/A
9/30/2022	1,580	745	459	495	N/A
6/30/2022	1,438	558	277	315	N/A
3/31/2022	1,342	354	201	242	N/A
12/31/2021	1,288	452	302	341	N/A
9/30/2021	1,232	448	148	185	N/A
6/30/2021	1,168	401	894	928	N/A
3/31/2021	1,703	880	856	899	N/A
12/31/2020	1,660	781	1,006	1,056	N/A
9/30/2020	1,736	889	1,122	1,166	N/A
6/30/2020	1,559	853	357	399	N/A
3/31/2020	837	349	361	383	N/A
12/31/2019	806	325	182	199	N/A
9/30/2019	532	223	183	198	N/A
6/30/2019	487	178	N/A	190	N/A
3/31/2019	441	202	N/A	180	N/A
12/31/2018	464	226	N/A	156	N/A
9/30/2018	437	222	N/A	165	N/A
6/30/2018	397	194	N/A	140	N/A
3/31/2018	462	213	N/A	215	N/A
12/31/2017	381	178	N/A	256	N/A
9/30/2017	361	184	N/A	200	N/A
6/30/2017	356	208	N/A	218	N/A
3/31/2017	272	174	N/A	156	N/A
12/31/2016	257	168	N/A	46	N/A
9/30/2016	221	111	N/A	99	N/A
6/30/2016	205	102	N/A	88	N/A
3/31/2016	183	82	N/A	55	N/A
12/31/2015	165	111	N/A	45	N/A
9/30/2015	116	66	N/A	10	N/A
6/30/2015	115	69	N/A	3	N/A
3/31/2015	102	60	N/A	14	N/A

アナリストによる今後の成長予測

収入対貯蓄率: GMABの予測収益成長率 (年間8.8% ) は貯蓄率 ( 1.7% ) を上回っています。

収益対市場: GMABの収益 ( 8.8% ) はDanish市場 ( 5.9% ) よりも速いペースで成長すると予測されています。

高成長収益: GMABの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: GMABの収益 ( 10.3% ) Danish市場 ( 4.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: GMABの収益 ( 10.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: GMABの自己資本利益率は、3年後には高くなると予測されています ( 32.3 %)

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/01/07 10:13
終値	2026/01/07 00:00
収益	2025/09/30
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Genmab A/S 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。45

アナリスト	機関
James Gordon	Barclays
Xue Chen	Barclays
Emily Field	Barclays

Genmab 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Genmab Provides Earnings Guidance for the Full Year 2025

Consensus EPS estimates increase by 10%, revenue downgraded

Genmab A/S Raises Earnings Guidance for the Year 2025

Genmab A/S Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Consensus EPS estimates increase by 16%

Genmab A/S Just Beat EPS By 44%: Here's What Analysts Think Will Happen Next

Recent updates

Genmab A/S to Discontinue Further Clinical Development of Acasunlimab Following A Portfolio Review

Genmab A/S (CPSE:GMAB) completed the acquisition of Merus N.V. (NasdaqGM:MRUS) in a tender offer transaction.

Senior Director recently sold kr.343k worth of stock

Genmab A/S Announces EPKINLY (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

Genmab A/S to Report First Half, 2026 Results on Aug 06, 2026

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Genmab Provides Earnings Guidance for the Full Year 2025

Genmab A/S Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®?) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

Investor sentiment improves as stock rises 16%

Genmab Reportedly in Advanced Talks to Buy Merus

Here's Why We Think Genmab (CPH:GMAB) Might Deserve Your Attention Today

Co-Founder exercised options to buy kr.42m worth of stock.

Genmab A/S Announces Updated Results from Phase 2 Epcore®? Nhl-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl)

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 10%, revenue downgraded

Genmab A/S Raises Earnings Guidance for the Year 2025

Investors Aren't Entirely Convinced By Genmab A/S' (CPH:GMAB) Earnings

Genmab Announces Changes to Its Executive Committee

Genmab A/S Announces Investigational Rinatabart Sesutecan (Rina-S) Demonstrates Encouraging Anti-Tumor Activity Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL-01 Trial

Genmab A/S to Present New and Updated Results from Its Robust Epcoritamab (Epkinly®) Development Program At the 2025 European Hematology Association (Eha) Congress

Genmab A/S Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Genmab A/S to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed Refractory Follicular Lymphoma

Genmab A/S Announces Japan Ministry of Health, Labour and Welfare Approves TIVDAK for the Treatment of Advanced or Recurrent Cervical Cancer

Genmab A/S Updates Data from Cohort B1 of the Phase 1/2 RAINFOL-01 Study of Rina-S

Investor sentiment deteriorates as stock falls 16%

It's Unlikely That The CEO Of Genmab A/S (CPH:GMAB) Will See A Huge Pay Rise This Year

Consensus EPS estimates increase by 16%

Genmab A/S Just Beat EPS By 44%: Here's What Analysts Think Will Happen Next

Genmab A/S, Annual General Meeting, Mar 12, 2025

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Genmab A/S Provides Revenue Guidance for 2025

Insufficient new directors

Genmab A/S Announces New Results from the Phase 1b/2 EPCORE NHL-2 Trial

Decisive Advances And DuoBody Innovation Propel Future Growth In Biotech Frontiers

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Co-Founder exercised options to buy kr.45m worth of stock.

Second quarter 2024 earnings released: EPS: kr.21.85 (vs kr.20.46 in 2Q 2023)

Consensus EPS estimates fall by 15%

Genmab A/S Takes Full Control of Acasunlimab Development Program

Consensus EPS estimates increase by 14%

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Non-Independent Director recently sold kr.3.8m worth of stock

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Consensus EPS estimates fall by 11%

First quarter 2024 earnings released: EPS: kr.20.29 (vs kr.3.46 in 1Q 2023)

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Executive VP & CFO recently sold kr.22m worth of stock

Executive VP & CFO exercised options to buy kr.22m worth of stock.

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Full year 2023 earnings: EPS misses analyst expectations

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: kr.32.60 (vs kr.39.55 in 3Q 2022)

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Investor sentiment deteriorates as stock falls 16%